RedHill Biopharma Ltd. Announces First Patients Dosed In Phase 3 Study Of RHB-105 For H. Pylori Infection
Published: Dec 17, 2013
TEL-AVIV, Israel, Dec. 17, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs, today announced that the first patients have been dosed in the Phase III ERADICATE Hp clinical study in the U.S.
Help employers find you! Check out all the jobs and post your resume.